Melanotan II Dosage Guide: Protocols, Calculator & Safety

Heavy disclaimer: MT-II is not approved for human use, product quality varies, and significant dermatologic risks exist. This educational summary describes protocols circulated in peptide-user communities, not medical recommendations. Anyone proceeding should do so with a dermatologist's involvement and baseline mole mapping.

Goal of the beginner protocol: Establish tolerance, minimize nausea, and build a modest baseline tan that can be maintained with UV exposure (real sun or tanning beds) during the consolidation phase.

Reconstitution: A 10 mg vial of lyophilized MT-II reconstituted with 2 mL of bacteriostatic water yields a 5 mg/mL solution. Each 0.01 mL on an insulin syringe (1 unit) delivers 50 mcg.

Loading Phase (weeks 1-3):

• Days 1-3: 100 mcg subcutaneous each evening before bed. This is a deliberately small starter dose to test for acute hypersensitivity and establish nausea baseline. Many users can sleep through the nausea peak by dosing at 9-10 PM.
• Days 4-7: 250 mcg subcutaneous each evening if day 1-3 doses were tolerated.
• Week 2: 500 mcg subcutaneous each evening (if still well tolerated) or 250 mcg twice daily if single doses produce too much acute nausea.
• Week 3: 500-750 mcg daily, with UV exposure (10-15 minutes of sun or 5-7 minutes of moderate tanning bed) 2-3 times per week to accelerate melanogenesis. Without any UV stimulus, MT-II produces only a modest baseline tan — MT-II amplifies the tanning response to UV, it does not replace UV.

Typical week-2 signs that loading is working:

• Existing moles and freckles darkening noticeably
• Skin over elbows, knees, and scars taking on slight yellow-brown tint
• Mild nausea in the 30-90 min after injection (diminishing with each dose)
• Some libido increase and/or spontaneous morning erections in men

Consolidation / Maintenance Phase (weeks 4-8): Once desired skin tone is reached (usually 2-3 weeks of loading + intermittent UV), drop frequency to 500-1000 mcg once or twice weekly to maintain pigmentation. At maintenance frequency, acute side effects largely disappear. Continue UV exposure 1-2x weekly for color maintenance — without any UV, tan fades over 4-6 weeks as keratinocytes carrying melanin turn over.

Cycle length: Most users run MT-II for 8-12 weeks total (3-week loading + 6-8 week maintenance) followed by a complete break. Taking an off-period lets pigmentation normalize, gives the body time to clear any peptide impurities, and — most importantly — creates a window for dermatologic mole mapping without MT-II-induced darkening confounding the exam.

What to watch for and stop dosing immediately:

• Any mole that changes shape, border, or color distinctly — not just uniform darkening. Seek dermatologic evaluation.
• Priapism (erection lasting >4 hours) — emergency evaluation.
• Chest pain, severe headache, or blood pressure persistently >160/100 — cardiology evaluation.
• New-onset rash, hives, or facial swelling suggesting allergic reaction.
• Dark cola-colored urine or severe diffuse muscle pain (rhabdomyolysis concern).

For users who have completed at least one beginner cycle without adverse events and want faster or deeper pigmentation.

Accelerated Loading (weeks 1-2 only):

• Day 1: 250 mcg evening dose
• Days 2-3: 500 mcg evening dose
• Days 4-7: 500 mcg twice daily (morning + evening)
• Week 2: 1 mg evening dose daily
• Week 3: Transition to maintenance at 500-1000 mcg twice weekly

Accelerated protocols compress the loading timeline but amplify acute side effects — particularly nausea, blood pressure rise, and facial flushing. They require substantially better nausea tolerance and should not be attempted until a conventional beginner cycle has established good individual response.

UV Synergy Strategy: Schedule a moderate tanning bed session (5-8 minutes in a Type 3 bed) 2-3 hours after the evening MT-II dose. This coincides peak plasma MT-II with fresh UV stimulation, driving much more efficient melanogenesis than either alone. Do NOT extend UV sessions beyond what you would normally tolerate without MT-II — the UV dose that burns you without MT-II still burns you with MT-II; MT-II darkens the tan but does not protect against erythema.

Targeted Pigmentation: Some users want tan body with minimal facial darkening (to avoid obvious new freckling). Applying broad-spectrum SPF 50+ to the face during UV exposure while tanning the body allows for relatively selective body tanning. Facial darkening that does occur tends to be more spotty (ephelides, new freckles on existing sun damage) rather than uniform — this is why many experienced MT-II users consider facial application of sunscreen non-negotiable.

Dose Fractionation: Instead of a single 1 mg evening dose, split into 500 mcg morning + 500 mcg evening. This smooths the plasma curve, reduces peak-dose nausea, and produces similar tanning response.

Maintenance Length: Experienced users often run 12-16 week cycles (longer maintenance phase) rather than the 8-12 week beginner range. At maintenance frequency, systemic side effects are minimal.

Still recommended:

• Dermatologic mole mapping before and after each cycle
• Blood pressure monitoring if any baseline hypertension
• Non-negotiable off-period between cycles (minimum 6-8 weeks)

For experienced users with multiple successful cycles and established dermatologic surveillance.

Advanced MT-II protocols do not typically involve higher doses — the dose-response for pigmentation plateaus around 1 mg, and higher doses mostly produce more side effects without more tan. Instead, advanced protocols focus on:

1. Minimizing cycle burden by using smaller, more frequent maintenance doses rather than large periodic loads. Some experienced users run indefinite maintenance at 250-500 mcg 2x weekly rather than repeated load-cycle-off patterns. The cumulative peptide exposure and mole-mapping complications of this pattern have never been studied and caution is warranted.

2. Integrating with afamelanotide for users who have access to clinical afamelanotide (Scenesse) for a medical indication. Some dermatology patients on afamelanotide use MT-II during the interval between implants to bridge pigmentation; this approach is unstudied and stacks MC1R agonism from both sources.

3. Coordinating with body-composition peptide cycles. The appetite suppression, water retention, and subtle metabolic effects of MT-II can complicate interpretation of cutting cycles involving Tirzepatide or Retatrutide. Advanced users often schedule MT-II courses for maintenance phases rather than active cut phases to avoid confounding the body-composition response.

4. Fine-tuning injection site rotation. Because MT-II's pigmentation effect is systemic rather than local, injection-site selection doesn't drive tan distribution. However, repeated injection into the same subcutaneous area can produce localized fibrosis and nodule formation. Rotating among abdomen, flanks, outer thighs, and upper buttocks on a systematic schedule avoids this.

Advanced Cautions:

• Cumulative lifetime MT-II exposure is a variable nobody has studied. Users running repeated cycles year after year are the informal long-term safety cohort, and their outcomes aren't tracked. Annual dermatologist visits with full-body photography become progressively more important with each cycle.
• Any new, darkening, or changing nevus during an advanced user's cycle should trigger dermatologic evaluation with a low threshold for biopsy.
• Blood pressure should be rechecked each cycle. Chronic melanocortin receptor stimulation may have cumulative cardiovascular effects that are not yet recognized.
• Pregnancy planning: MT-II has no safety data in pregnancy. Users planning conception should complete a full off-cycle washout (minimum 3 months) before attempting pregnancy.

When to stop advanced MT-II use permanently:

• New diagnosis of any primary melanoma
• Discovery of BRCA, CDKN2A, or other genetic cancer predisposition
• Development of hypertension requiring medication
• Any cardiovascular event
• Pregnancy or pregnancy planning
• Age > 50 with accumulating photodamage — transitioning to afamelanotide under dermatologic care becomes a more defensible option at this stage.